These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 30719268)

  • 1. Immunotherapy in myeloma: how far have we come?
    Franssen LE; Mutis T; Lokhorst HM; van de Donk NWCJ
    Ther Adv Hematol; 2019; 10():2040620718822660. PubMed ID: 30719268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and future prospects of immunotherapy for multiple myeloma].
    Imai Y
    Rinsho Ketsueki; 2021; 62(5):407-417. PubMed ID: 34108322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.
    Nishida H; Yamada T
    J Oncol; 2019; 2019():6084012. PubMed ID: 31781214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging immunotherapies in multiple myeloma.
    Shah UA; Mailankody S
    BMJ; 2020 Sep; 370():m3176. PubMed ID: 32958461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Multiple Myeloma.
    Tamura H; Ishibashi M; Sunakawa M; Inokuchi K
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31842518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
    D'Souza C; Prince HM; Neeson PJ
    Front Immunol; 2021; 12():632399. PubMed ID: 33746969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij CPM; Korst CLBM; van de Donk NWCJ
    Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma.
    Mohan M; Maatman TC; Schinke C
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current treatment of refractory and relapsed multiple myeloma].
    Sasaki M
    Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematologic Malignancies: Plasma Cell Disorders.
    Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
    Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenges of checkpoint inhibition in the treatment of multiple myeloma.
    Paul B; Kang S; Zheng Z; Kang Y
    Cell Immunol; 2018 Dec; 334():87-98. PubMed ID: 30342750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
    Abramson HN
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma.
    Zhou X; Einsele H; Danhof S
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32659909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].
    Tamura H
    Rinsho Ketsueki; 2018; 59(10):2169-2177. PubMed ID: 30305523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of Multiple Myeloma: Promise and Challenges.
    Abramson HN
    Immunotargets Ther; 2021; 10():343-371. PubMed ID: 34527606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review.
    Nishida H
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How is patient care for multiple myeloma advancing?
    Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
    Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.